| Kimberly Porter, | |
|
9 Courthouse Dr, Winfield, WV 25213-9347 | |
| (304) 586-0500 | |
| (304) 586-0553 |
| Full Name | Kimberly Porter |
|---|---|
| Gender | Female |
| Speciality | Speech-language Pathologist |
| Location | 9 Courthouse Dr, Winfield, West Virginia |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1972771145 | NPI | - | NPPES |
| 9409048000 | Medicaid | WV |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 235Z00000X | Speech-language Pathologist | 3398 (West Virginia) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Kimberly Porter, 501 22nd St, Dunbar, WV 25064-1711 Ph: (304) 766-7655 | Kimberly Porter, 9 Courthouse Dr, Winfield, WV 25213-9347 Ph: (304) 586-0500 |
News Archive
A recent study published on the preprint server bioRxiv* seeks to establish the pattern of antibody reactivity in COVID-19 convalescent plasma (CCP), which is widely being used as a therapy for seriously ill COVID-19 patients.
A study led by the University of Warwick has found a link between the removal of ovaries during hysterectomy and an increase in heart disease, cancer and premature death.
The head of the World Health Organization has said that air pollution is the "new tobacco" and breathing polluted air is killing 7 million people annually and harming billions of the population additionally.
Nitto Denko Corporation, Japan's leading diversified materials manufacturer and Quark Pharmaceuticals, Inc., a world leader in the discovery and development of RNAi-based therapeutics, today announced the initiation of a collaboration and license agreement for the development of siRNA therapeutics for the treatment of fibrotic diseases.
Covidien, a leading global provider of healthcare products, announced the results of an analysis that will be presented at the American College of Rheumatology's Annual Scientific Meeting. A pooled analysis of safety data suggests that patients with knee osteoarthritis (OA) receiving the topical PENNSAID® (diclofenac sodium topical solution) 1.5% w/w had significantly fewer gastrointestinal (GI)-related adverse events than those receiving an oral non-steroidal anti-inflammatory drug (NSAID).
› Verified 8 days ago
Katy Marie Snider, M.S., CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 431 Woodberry Way, Winfield, WV 25213 Phone: 717-636-0258 | |
Sara Parker, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 9 Courthouse Dr, Winfield, WV 25213 Phone: 304-586-0500 Fax: 304-586-0553 | |
Laura Whittington, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 9 Courthouse Dr, Winfield, WV 25213 Phone: 304-586-0500 Fax: 304-586-0553 | |
Lisa Ratliff, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 9 Courthouse Dr, Winfield, WV 25213 Phone: 304-586-0500 Fax: 304-586-0553 | |
Kristen Renee Smith, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 1450 Bills Creek Rd, Winfield, WV 25213 Phone: 304-941-3701 | |
Claudia Fizer, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 9 Courthouse Dr, Winfield, WV 25213 Phone: 304-586-0500 Fax: 304-586-0553 | |
Linda Reber, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 9 Courthouse Dr, Winfield, WV 25213 Phone: 304-586-0500 Fax: 304-586-0553 |